Last reviewed · How we verify
capecitabine-irinotecan
Capecitabine-irinotecan combines a prodrug of fluorouracil with a topoisomerase I inhibitor to target rapidly dividing cancer cells.
Capecitabine-irinotecan combines a prodrug of fluorouracil with a topoisomerase I inhibitor to target rapidly dividing cancer cells. Used for Metastatic colorectal cancer.
At a glance
| Generic name | capecitabine-irinotecan |
|---|---|
| Sponsor | Dutch Colorectal Cancer Group |
| Drug class | Topoisomerase I inhibitor and thymidylate synthase inhibitor |
| Target | Topoisomerase I and thymidylate synthase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Capecitabine is converted into 5-fluorouracil, which is then phosphorylated into its active form, 5-fluorodeoxyuridylate. This inhibits thymidylate synthase, leading to DNA damage and cell death. Irinotecan, on the other hand, inhibits topoisomerase I, preventing DNA replication and transcription.
Approved indications
- Metastatic colorectal cancer
Common side effects
- Diarrhea
- Fatigue
- Nausea
- Vomiting
- Neutropenia
Key clinical trials
- Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44) (PHASE2)
- Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases (PHASE2, PHASE3)
- SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC (NA)
- Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer (PHASE3)
- A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer (PHASE1)
- Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (PHASE2, PHASE3)
- Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer (PHASE3)
- A Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regimen as First-line Treatment for Unresectable Advanced Colorectal Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- capecitabine-irinotecan CI brief — competitive landscape report
- capecitabine-irinotecan updates RSS · CI watch RSS
- Dutch Colorectal Cancer Group portfolio CI